Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT02734004
Title A Phase I/II Study of MEDI4736 in Combination With Olaparib in Patients With Advanced Solid Tumors. (MEDIOLA)
Recruitment Active, not recruiting
Gender both
Phase Phase Ib/II
Variant Requirements Yes
Sponsors AstraZeneca

stomach cancer

breast cancer

ovarian cancer

lung small cell carcinoma


Durvalumab + Olaparib

Bevacizumab + Durvalumab + Olaparib

Age Groups: adult | senior
Covered Countries USA | FRA

Additional content available in CKB BOOST